GlaxoSmithKline Czech Republic's net debt stood at CZK -209 mil and accounted for -13.8% of equity at the end of 2017. The ratio is up 9.22 pp compared to the previous year.
Historically, the firm’s net debt to equity reached a high of 40.0% in 2008 and a low of -38.5% in 2015 between 2003 and 2017. The average for the last five years was -10.3%.
Net debt to EBITDA was calculated at -2.15x at the end of the year. That is down from 1.02x seen in 2012. The ratio reached a high of 2.74x in 2008 and a low of -5.61x in 2016.
The company’s cost of funding amounted to in 2017, down which is above the 5-year of 1.68%. Funding costs have “eaten” some 0.954% of the operating profit generated in 2019.
You can see all the company’s data at GlaxoSmithKline Czech Republic profile, or you can download a report on the company in the report section.
Helgi Library 
